Compound Profiles

QR-333

Diabetic Peripheral Neuropathy

  Concentrated and standardized nutrient based active compound dozed in a topical cream designed to reduce oxidative stress and treat symptom of Diabetic peripheral neuropathy, a nerve disorder that can lead to numbness, constant pain or extreme sensitivity to a stimulus.

+ More

 

QR-435, QR-447, QR-448, QR-441

Broad Spectrum Antiviral


The constituent components of the formulation platform are derivatives of Spice type plants that have been shown to have antiviral properties when used synergistically. In particular, but not limited to, the compound has demonstrated the ability to reduce transmissivity and/or provide antiviral activity against:

Influenza types A & B in ferret models
New Castle Disease in poultry
Infectious Bronchitis in poultry
Avian Flu H5N1 in poultry

 

QR-440, QR-440(c)

Arthritis

  A botanical compound of concentrated spice type plant Derivatives, QR-440 has been shown in pre-clinical studies to have a significant anti-inflamatory effect.

+ More

 

Safe Harbor Statement for Research and Development

The Quigley Corporation makes no representation that the US Food and Drug Administration or any other regulatory agency will grant an Investigational New Drug ("IND") or take any other action to allow its formulations to be studied or/and for any Investigational New Drug to be marketed. Furthermore, no claim is made that potential medicine discussed herein is safe, effective, or approved by the Food and Drug Administration. Additionally, data that demonstrates activity or effectiveness in animals or in vitro tests do not necessarily mean the formula test compound, referenced herein will be effective in humans. Safety and effectiveness in humans will have to be demonstrated by means of adequate and well controlled clinical studies before the clinical significance of the formula test compound is known. Readers should carefully review the risk factors described in filings the Company files from time to time with the Securities and Exchange Commission.

 

[detail_module_foot.gif]